Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting-Reference-Cited by-同舟云学术

Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting

Published:2021-07 Issue:19 Volume:17 Page:2439-2448
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Waterhouse David M¹^ORCID,Nwokeji Esmond D²,Boyd Marley²,Penrod John R³,Espirito Janet L²,Robert Nicholas J²,Daumont Melinda J⁴

Affiliation:

1. Oncology Hematology Care, Cincinnati, OH 45242, USA

2. McKesson Life Sciences, The Woodlands, TX 77380, USA

3. Bristol Myers Squibb, Princeton, NJ 08540, USA

4. Bristol Myers Squibb, Braine-l'Alleud, Belgium

Abstract

Aim: To assess real-world treatment patterns and outcomes among patients with advanced malignant pleural mesothelioma. Patients & methods: Retrospective database analysis. Results: In all, 469 patients received first-line systemic anticancer therapy (SACT) at community centers. Median follow-up from diagnosis was 11.6 months. Pemetrexed + platinum was the most common first-line SACT; similar proportions of patients received cisplatin or carboplatin with pemetrexed. Only a small proportion of patients received second- and third-line therapies. Median overall survival for first-line SACT was 12.0 months (95% CI: 10.7–14.2). Results were similar with pemetrexed + cisplatin and pemetrexed + carboplatin. Median overall survival with second-line SACT was 6.4 months (95% CI: 5.1–7.6). Conclusion: There is a need for more effective SACTs for advanced malignant pleural mesothelioma.

Funder

Bristol Myers Squibb

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2021-0047

Reference32 articles.

1. Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients

2. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment

3. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: malignant pleural mesothelioma v2.2021. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for malignant pleural mesothelioma V.2.2021©. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. (2021). https://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf

4. Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma?;Lung Cancer;2024-08

2. Malignant and borderline mesothelial tumors of the pleura;Practical Pulmonary Pathology;2024

3. Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group;Current Problems in Cancer;2023-12

4. Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways;Translational Lung Cancer Research;2022-04